Prognostic significance of clinical factors and p53 expression in patients with glottic carcinoma treated with radiation therapy

Cancer

Volumn 78, Issue 8, 1996, Pages 1693-1700

  Kokoska, Mimi S ^a   Piccirillo, Jay F ^a   El Mofty, Samir K ^a   Emami, Bahman ^a   Haughey, Bruce H ^a   Scholnick, Steven B ^a,b  

^a WASHINGTON UNIVERSITY   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

immunohistochemistry; laryngeal neoplasms; p53; prognosis; prognostic factors; radiation resistance; squamous cell carcinoma

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CONTROLLED STUDY; EPIGLOTTIS CANCER; FEMALE; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RADIOSENSITIVITY; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029738901     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19961015)78:8<1693::AID-CNCR9>3.0.CO;2-F     Document Type: Article

References (42)

1. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin 1995;45:8-30.
2. Sessions RB, Harrison LB, Hong WK. Tumors of the larynx and hypopharynx. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 4th edition. Philadelphia: J.B. Lippincott Co., 1993:631-55.
3. Ganzer U. Prognosis of laryngeal cancer since 1960. Results of a literature review and a survey. Laryngorhinootologie 1990;69:1-5.
4. Rockley TR, Robin PE, Powell J, McConkey CC. Primary treatment of cancer of the larynx. J Laryngol Otol 1991;105:459-62.
5. Monyak K, Levitt S. Radiation therapy of head and neck cancer. In: Paparella MM, Shumrick DA, Gluckman JL, Meyerhoff WL, editors. Otolaryngology. 3rd ed. Philadelphia: W.B. Saunders, 1991:3183-230.
6. Gelinas M, Fletcher GH. Incidence and causes of local failure of irradiation in squamous cell carcinoma of the faucial arch, tonsillar fossa and base of the tongue. Radiology 1973;108:383-7.
7. Wall TJ, Peters LJ, Brown BW, Oswald MJ, Milas L. Relationship between lymph nodal status and primary tumor control probability in tumors of the supraglottic larynx. Int J Radiat Oncol Biol Phys 1985;1:1895-902.
8. Bush RS, Jenkin RD, Allt WE, Beale FA, Bean H, Dembo AJ, et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer Suppl 1978;37:302-6.
9. Harwood AR, Deboer G, Kazim F. Prognostic factors in T3 glottic cancer. Cancer 1981;47:367-72.
10. van Acht MJ, Hermans J, Boks DE, Leer JW. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992;23:229-35.
11. Kersh CR, Kelly MD, Hahn SS, Spaulding CA, Cantrell RW, Constable WC. Early glottic carcinoma: patterns and predictors of relapse after definitive radiotherapy. South Med J 1990;83:374-8.
12. Rudoltz MS, Benammar A, Mohiuddin M. Prognostic factors for local control and survival in T1 squamous cell carcinoma of the glottis. Int J Radiat Oncol Biol Phys 1993;26:767-72.
13. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
14. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;51:6304-11.
15. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993;362:847-9.
16. Lee JM, Bernstein A. p53 mutations increase resistance to ionizing radiation. Proc Natl Acad Sci USA 1993;90:5742-6.
17. Kastan MB, Zhan Q, el-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;71:587-97.
18. Pardo FS, Su M, Borek C, Preffer F, Dombkowski D, Gerweck L, et al. Transfection of rat embryo cells with mutant p53 increases the intrinsic radiation resistance. Radiat Res 1994;140:180-5.
19. Jung M, Notario V, Dritschilo A. Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 1992;52:6390-3.
20. Brachman DG, Beckett M, Graves D, Haraf D, Vokes E, Weichselbaum RR. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines. Cancer Res 1993;53:3667-9.
21. Piccirillo JF, Wells CK, Sasaki CT, Feinstein AR. New clinical severity staging system for cancer of the larynx. Five-year survival rates. Ann Otol Rhinol Laryngol 1994;103:83-92.
22. Kaplan MH, Feinstein AR. The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitus. J Chronic Dis 1974;27:387-404.
23. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis 1970;23:455-68.
24. Beahrs O, Henson DE, Hutter RVP, Myers MH. Manual for staging of cancer, 3rd ed. Philadelphia: J.B. Lippincott Co., 1988;39-41.
25. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Manual for Staging Cancer. 4th edition. Philadelphia: J.B. Lippincott Co., 1992:39-41.
26. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J Immunol Methods 1992;151:237-44.
27. Gannon JV, Greaves R, Iggo R, Lane DP. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 1990;9:1595-602.
28. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
29. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992;340:259-63.
30. Maestro R, Dolcetti R, Gasparotto D, Doglioni C, Pelucchi S, Barzan L, et al. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. Oncogene 1992;7:1159-66.
31. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning, a laboratory manual. 2nd edition. Volume 3. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 1989.
32. Pavelic ZP, Portugal LG, Gootee MJ, Stambrook PJ, Smith C, Mugge RE, et al. Retrieval of p53 protein in paraffin-embedded head and neck tumor tissues. Arch Otolaryngol Head Neck Surg 1993;119:1206-9.
33. Watling DL, Gown AM, Coltrera MD. Overexpression of p53 in head and neck cancer. Head Neck 1992;14:437-44.
34. Boyle JO, Hakim J, Koch W, van der Riet P, Hruban RH, Roa RA, et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993;53:4477-80.
35. Gapany M, Pavelic ZP, Gapany SR, Pavelic L, Li YG, Craven JM, et al. Relationship between immunohistochemically detectable p53 protein and prognostic factors in head and neck tumors. Cancer Detect Prev 1993;17:379-86.
36. Sarbia M, Forschen R, Borchard F, Horstmann O, Willers R, Gabber HE. p53 protein expression and prognosis in squamous cell carcinoma of the esophagus. Cancer 1994;74:218-23.
37. Bradford CR, Zhu SB, Wolf GT, Poore J, Fisher SG, Beals T, et al. Overexpression of p53 predicts organ preservation using induction chemotherapy and radiation in patients with advanced laryngeal cancer. Otolaryngol Head Neck Surg 1995;113:408-12.
38. Ahomadegbe JC, Barrois M, Fogel S, Le Bihan ML, Douc-Rasy S, Duvillard P, et al. High incidence of p53 alterations (mutation, deletion, overexpression) in head and neck primary tumors and metastases; absence of correlation with clinical outcome. Frequent protein overexpression in normal epithelium and in early non-invasive lesions. Oncogene 1995;10:1217-27.
39. Field JK, Malliri A, Butt SA, Gosney IR, Phillips D, Spandidos DA, et al. p53 expression in end stage squamous cell carcinoma of the head and neck prior to chemotherapy: expression correlates with a very poor prognosis. Int J Oncol 1993;3:431-5.
40. Kocialkowski S, Pezzella F, Morrison H, Jones M, Laha S, Harris AL, et al. Mutations in the p53 gene are not limited to classic 'hot spots' and are not predictive of p53 protein expression in high-grade non-Hodgkin's lymphoma. Br J Haematol 1995;89:55-60.
41. Fisher CJ, Gillett CE, Vojtesek B, Barnes DM, Millis RR. Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer 1994;69:26-31.
42. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 1992;89:7491-5.